Sanofi to Acquire UK-Based Vicebio in $1.6 Billion Deal to Advance Respiratory Vaccine Innovation
NewsVicebio’s ‘Molecular Clamp’ technology to bolster Sanofi’s respiratory vaccine pipeline targeting RSV and hMPV French pharmaceutical giant Sanofi has signed a definitive agreement to acquire Vicebio, a UK-based biotechnology firm specializing in respiratory virus vaccines, in a deal valued at up to $1.6 billion. This strategic acquisition strengthens Sanofi’s position in next-generation vaccine development and […]